The applied cytokine treatments cause a distinct and characteristic change in transcription factors (RORC and TBX21) and cytokine production (IL-17A and IL-22) of healthy donors, RA, and PsA patients (Figures 4 and 5; Figure S5 in Supplementary Material). The gene discussed is IL17A; the disease is rheumatoid arthritis.